Quantitative Spatial Profiling of PD-1/PD-L1 Interaction in Patients with Cancer

Overview

Journal Transl Lung Cancer Res

Date 2023 Jul 10

PMID 37425418

Authors

Taiki Hakozaki

Affiliations

Soon will be listed here.

References

Swetter S, Thompson J, Albertini M, Barker C, Baumgartner J, Boland G . NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(4):364-376. DOI: 10.6004/jnccn.2021.0018. View

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

Sanchez-Magraner L, Miles J, Baker C, Applebee C, Lee D, Elsheikh S . High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res. 2020; 80(19):4244-4257. DOI: 10.1158/0008-5472.CAN-20-1117. View

Reck M, Remon J, Hellmann M . First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):586-597. DOI: 10.1200/JCO.21.01497. View

Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung T, Shafi S . Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021; 28(2):360-367. PMC: 8776595. DOI: 10.1158/1078-0432.CCR-21-2649. View

Giraldo N, Nguyen P, Engle E, Kaunitz G, Cottrell T, Berry S . Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer. 2018; 6(1):99. PMC: 6167897. DOI: 10.1186/s40425-018-0404-0. View

Johnson D, Bordeaux J, Kim J, Vaupel C, Rimm D, Ho T . Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018; 24(21):5250-5260. PMC: 6214750. DOI: 10.1158/1078-0432.CCR-18-0309. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329-359. DOI: 10.6004/jnccn.2021.0012. View

10.

Yu H, Boyle T, Zhou C, Rimm D, Hirsch F . PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016; 11(7):964-75. PMC: 5353357. DOI: 10.1016/j.jtho.2016.04.014. View